Trial Profile
Randomized phase I/II Pilot study of the immunogenicity of cyclophosphamide with peptide pulsed mature dendritic cells for patients with previously treated ovarian epithelial or primary peritoneal carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines (Primary) ; Cyclophosphamide; Pneumococcal vaccine
- Indications Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms DC-Ova
- 26 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jan 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 05 May 2008 Status changed from recruiting to in progress, reported by ClinicalTrials.gov.